Table 3.
Median proportion of three types of monocytes and monocyte subsets with PD-L1 expression between patients with COVID-19 and convalescent COVID-19 patients. Data expressed as median (Q1–Q3). (* p < 0.05 Mann–Whitney U test).
| Patients with COVID-19 Median (Q1–Q3) |
Convalescent Median (Q1–Q3) |
* p < 0.05 Mann–Whitney U Test |
|
|---|---|---|---|
| All monocytes [% of leukocytes] | 5.5 (3.8–7.6) | 7.0 (4.6–9.1) | * 0.037130 |
| [% of monocytes] | |||
| Classical monocytes CD14++ CD16- | 83.2 (76.5–87.1) | 84.2 (76.9–88.8) | 0.460992 |
| Intermediate monocytes CD14+ CD16+ | 7.5 (4.4–15.7) | 7.7 (5.6–11.7) | 0.904777 |
| Non classical monocytes CD14−/+ CD16++ | 0.9 (0.3–1.8) | 2.2 (1.1–4.3) | * 0.000098 |
| PD-L1+ monocytes [%] | 33.8 (22.4–52.5) | 29.6 (15.7–60.3) | 0.659322 |
| PD-L1+ classical monocytes [%] | 18.1 (11.4–34.3) | 15.5 (7.5–46.3) | 0.659322 |
| PD-L1+ intermediate monocytes [%] | 73.1 (52.1–84.4) | 57.6 (38.4–71.9) | * 0.007261 |
| PD-L1+ non-classical monocytes [%] | 75.0 (62.5–85.7) | 77.8 (64.8–86.2) | 0.673065 |
| PD-L1+ monocytes [GeoMean] | 310 (247–435) | 276 (194–476) | 0.391353 |
| PD-L1+ classical monocytes [GeoMean] | 288 (222–412) | 237 (166–477) | 0.228186 |
| PD-L1+ intermediate monocytes [GeoMean] | 669 (523–919) | 530 (407–723) | * 0.015287 |
| PD-L1+ non-classical monocytes [GeoMean] | 728 (600–909) | 692 (558–832) | 0.427183 |
Abbreviation: GeoMean: geometric mean fluorescence intensity.